China
Africa
Explore chapters and articles related to this topic
Brucellosis
Published in Firza Alexander Gronthoud, Practical Clinical Microbiology and Infectious Diseases, 2020
The animal reservoir of B. melitensis is goats, sheep and camels, whilst B. abortus is found in cows, camels, yaks and buffalo. Brucella suis has been reported in pigs, wild hares, caribou and reindeer.
B
Published in Anton Sebastian, A Dictionary of the History of Medicine, 2018
Brucellosis (Syn. Bang disease, Mediterranean fever, undulant fever, Rock fever of Gibraltar. First named Malta fever) Sir David Bruce (1855–1931) isolated the bacterium responsible in the spleen of patients dying of the disease in Malta in 1887 and named it Micrococcus melitensis. The same organism, causing a widespread disease in cattle called ‘contagious abortion’, was discovered by Bernhard Bang (1848–1932) in 1897. The genus of bacteria was later named Brucella, by Karl Friedrich Meyer (b 1884) and E. Shaw of America in 1920. Brucella suis, the natural host of which is the pig, was described by J.E.Traum of America in 1914.
Infection
Published in Ashley W. Blom, David Warwick, Michael R. Whitehouse, Apley and Solomon’s System of Orthopaedics and Trauma, 2017
Brucellosis is an unusual but nonetheless important cause of subacute or chronic granulomatous infection in bones and joints. Three species of organism are seen in humans: Brucella melitensis, Brucella abortus (from cattle) and Brucella suis (from pigs). Infection usually occurs from drinking unpasteurized milk or from coming into contact with infected meat (e.g. among farmers and meat packers). In the past it has been more common in countries around the Mediterranean and in certain parts of Africa and India. About 50% of patients with chronic brucellosis develop arthritis.
The first activation study of the β-carbonic anhydrases from the pathogenic bacteria Brucella suis and Francisella tularensis with amines and amino acids
Published in Journal of Enzyme Inhibition and Medicinal Chemistry, 2019
Andrea Angeli, Sonia Del Prete, Mariana Pinteala, Stelian S. Maier, William A. Donald, Bogdan C. Simionescu, Clemente Capasso, Claudiu T. Supuran
The pathogenic bacteria Brucella suis1,2 and Francisella tularensis3,4 provoke serious diseases both in human and livestock, are difficult to treat by antibiotics, and have the potential to induce widespread infections. In fact, both Brucella and Francisella might be used as bioterrorism organisms due to the fact that quite low doses of pathogens (as few as 10–100 bacteria) are highly infectious, leading to ravaging epidemics1. Furthermore, they persist in the environment and are rapidly transmitted via different routes, including by aerosols and from human to human1. Brucellosis, like tularemia (the infection produced by F. tularensis) are neglected diseases, although their prevalence in humans and domestic/wild animals is not at all low1–4. These pathogens also became resistant to many currently used antibiotics1–4, with the danger that the treatment of infected patients/animals will become increasingly difficult. Thus, searching for new drug targets addressing these complex issues is of stringent relevance.
Inhibition studies of Brucella suis β-carbonic anhydrases with a series of 4-substituted pyridine-3-sulphonamides
Published in Journal of Enzyme Inhibition and Medicinal Chemistry, 2018
Simona Maria Monti, Angela Meccariello, Mariangela Ceruso, Krzysztof Szafrański, Jarosław Sławiński, Claudiu T. Supuran
Brucella suis is one of the bacteria responsible of brucellosis, a disease affecting an increasing number of people and which showed variable degrees of resistance to the clinically used antibiotics [1c,9–11]. Two β-class CAs were discovered in the genome of this pathogen, BsuCA1 and BsuCA29,10, which have also been investigated for their inhibition with various compounds, such as sulphonamides, sulphamates, anions, phenols, etc.9–12. Furthermore, the growth of the bacterium was also impaired (in cell cultures) by some of these inhibitors, which constitutes the proof-of-concept that BsuCA1/2 inhibition may have a significant antibacterial effect9. Continuing our interest in the discovery of CAIs which effectively target bacterial CAs, we report here an inhibition study of BsuCA1/2 with a class of pyridine-3-sulphonamide derivatives incorporating 4-heterocyclic/heteroaryl moieties, previously designed by our groups for targeting the tumor-associated human isoforms hCA IX and XII12. Some of the investigated sulphonamides from this article are among the most effective and isoform-selective BsuCA1 inhibitors ever reported.